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Serratia marcescens is an extremely rare cause of necrotizing fasciitis. We report the first case of necrotizing fasciitis of the chest
wall due to infection with S. marcescens that initially manifested as bilateral breast necrosis. The patient had a fulminant course
leading to death within 72 h of presentation. Literature pertinent to S. marcescens-mediated necrotizing fasciitis is also reviewed.
CASE REPORT
A54-year-old woman with a history of lupus and end-stagerenal disease requiring long-term dialysis presented with the
chief complaint of bilateral mastalgia for 4 days. Eighteen months
prior to presentation, the patient developed central venous cath-
eter-related superior vena cava (SVC) stenosis that proved refrac-
tory to angioplastic interventions. The subsequent clinical course
was marked by progressive symmetric enlargement of her breasts
from cup size B at baseline to larger than DD. A high-output left
upper extremity arteriovenous (AV) fistula—originally created to
provide hemodialysis access—appeared to be contributing to cen-
tral venous congestion and breast engorgement. Five days prior to
presentation, the AV fistula was ligated. The following day, the
patient developed severe pain in both her breasts. There was no
report of fever or chills. Home medications included 10 mg pred-
nisone per day for immune thrombocytopenic purpura. The pa-
tient denied prior or current alcohol or intravenous drug use.
Initial vital signs were as follows: temperature, 97.9°F; blood
pressure, 81/58 mmHg; heart rate, 114 beats per minute; respira-
tory rate, 22 breaths per minute; and arterial oxygen saturation,
96% while breathing room air. The general assessment was re-
markable for facial plethora and bilateral upper extremity swell-
ing. There was massive enlargement of both breasts with hyper-
pigmentation of overlying skin. The breasts were warm, tender,
and edematous, without any palpable masses or a nipple dis-
charge. The AV fistula ligation appeared uninfected. The patient
was noted to have no indwelling vascular access catheters.
On laboratory workup, a complete blood count revealed leu-
kopenia with left shift (white blood cells, 2.5  103 per mm3;
segmented neutrophils, 74%; bands, 9%; metamyelocytes, 5%;
myelocytes, 3%; lymphocytes, 5%; monocytes, 5%; and eosino-
phils, 1%) and thrombocytopenia (52,000 per mm3). A chemistry
panel showed ametabolic acidosis with an elevated lactic acid level
(4 mmol/liter). A test for human immunodeficiency virus (HIV)
was negative.
The patientwas diagnosedwith severe sepsis.Managementwas
initiated in accordancewith the institution’s severe sepsis and sep-
tic shock protocol. Two sets of blood cultures were obtained using
separate venipuncture sites, and an empirical antibiotic regimen
comprising vancomycin, piperacillin-tazobactam, and cipro-
floxacin was instituted. Blood culture bottles (BD Bactec Plus
Aerobic/F and BD Bactec Lytic/10 Anaerobic/F, 2 sets each) were
incubated in the BD Bactec FX blood culture system. Fourteen
hours later, the cultures turned positive. Gram staining revealed
the presence of a Gram-negative rod in 3 of 4 culture bottles.
Selective media were inoculated, with the following results: Mac-
Conkey agar showed the growth of a lactose nonfermenting or-
ganism; triple sugar iron (TSI) agar showed an alkaline/acid reac-
tion without gas formation; and phenylethyl alcohol (PEA) blood
agar showed no growth. Subsequent identification and antimicro-
bial susceptibility testing were carried out using the automated
Siemens MicroScan WalkAway96 system. The organism was fi-
nally identified to the species level as Serratia marcescens, with the
susceptibility profile shown in Table 1.
With worsening breast examination and rising lactic acid lev-
els, the patient was taken to the operating room, where both
breasts were confirmed to be nonviable and were removed. The
chest wall underneath the breasts demonstrated evidence of ne-
crotizing fasciitis and pectoral myonecrosis. A radical chest wall
debridement that included the pectoral fascia and the bulk of the
pectoralis major and pectoralis minormuscles bilaterally was per-
formed. Intraoperative cultures from the deep pectoral fascia also
grew back S. marcescenswith a susceptibility profile similar to that
of the organism growing from the blood (Table 1). The antibiotic
regimen was modified to doripenem to cover multidrug resis-
tance. However, the patient continued to deteriorate clinically
and, despite maximal supportive care, died of overwhelming sep-
tic shock.
Necrotizing fasciitis is an uncommon life-threatening soft tis-
sue infection (7). The clinical syndrome is characterized by wide-
spread subcutaneous fascial and fat necrosis associatedwith severe
systemic toxicity. Early debridement, intravenous antibiotics, and
supportive care are the cornerstones of therapy (12, 17). A variety
of microorganisms—Gram-positive cocci, Gram-negative rods,
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and anaerobes—have been implicated as etiologic agents. S.marc-
escens is an extremely rare cause of necrotizing fasciitis.
S. marcescens is a Gram-negative aerobic bacillus belonging to
the family Enterobacteriaceae. Serratia species are widely distrib-
uted in nature and in hospitals and may even be found as com-
mensals in the human gut microbiota. In recent years, S. marc-
escens has been increasingly recognized as an important and
frequent opportunistic pathogen. Serratia species rank among the
10most common causes of bacteremia (3) and skin and soft tissue
infections (13), accounting for 1.4% and 2.0% of cases, respec-
tively. Epidemiologic studies have shown an incidence rate of 1.3
cases of Serratia bacteremia per a population of 100,000 (6). A
substantial proportion (47%) of these events originates in the
community. Thus, Serratia is not a strict nosocomial pathogen
and frequently causes disease in nonhospital settings. Around a
third of patients with Serratia bacteremia are not alive 6 months
after diagnosis (6). While non-marcescens Serratia species may be
pathogenic, more than 90% of isolates in humans are S. marc-
escens (9). A high rate of antimicrobial resistance has not been
shown in epidemiologic studies, though a few reports do indicate
the presence of multidrug-resistant strains (1, 6, 9).
The exact mechanisms underlying the virulence of S. marc-
escens in humans are not completely known. Culture filtrates pre-
pared from S.marcescens are toxic tomammalian cells (4), includ-
ing human fibroblasts (14). S. marcescens secretes a broad array of
factors, including a hemolysin, a nuclease, a metalloprotease, ser-
ine proteases, siderophores, and lipases (1). Molecular studies
have shown a secreted 56-kDa metalloprotease (common to all S.
marcescens strains) to be a critical mediator of cytotoxicity in vitro
(11). Whether neutralization of this metalloprotease in vivo has
any therapeutic utility remains to be explored.
To identify previously reported cases of S. marcescens-medi-
ated necrotizing fasciitis, a Medline search was performed using
the search terms necrotizing fasciitis, Serratia, and Serratia marc-
escens. The search was limited to the English language literature
published between January 1966 and September 2011. Reference
lists of identified reports were also reviewed to find additional
cases of S. marcescens necrotizing fasciitis. As a result, 9 previously
reported cases were identified (Table 2) (2, 5, 8, 10, 15, 16, 19, 21).
Overall, a lower extremity was themost common site of infection,
being involved in 7 out of 10 (70%) patients. The present case
constitutes the first report of S. marcescens causing necrotizing
fasciitis of the chest wall.
A known immunocompromised state was not always identi-
fied in previous reports. None of the patients were infected with
HIV, even though all cases emerged after 1985. Several comorbidi-
ties and risk factors that might have contributed to enhanced sus-
ceptibility to infection with S. marcescens were noted. Advanced
renal disease was present in 4 of 10 patients, with 3 patients receiv-
ing scheduled hemodialysis. Corticosteroid use was reported in 3
of 10 patients. Three patients had diabetes mellitus, 2 had lupus,
and 1 had received chemotherapy for lung cancer. The antibiotic
TABLE 1 Antimicrobial susceptibility profile of S. marcescens isolates
from blood and breast tissue
Antibiotic
MIC (g/ml)a
Isolate from blood Isolate from breast
Amikacin 4 (S) 16 (S)
Amoxicillin/K clavulanate 16/8 (R)
Ampicillin 16 (I) 16 (R)
Ampicillin/sulbactam 16/8 (I) 16/8 (I)
Aztreonam 8 (S) 8 (S)
Cefotaxime 32 (R) 2 (S)
Cefotaxime/K clavulanate 4 4
Ceftazidime 4 (S) 1 (S)
Ceftazidime/K clavulanate 2 0.25
Ceftriaxone 32 (R) 8 (S)
Cefuroxime 16 (R) 16 (R)
Ciprofloxacin 1 (S) 1 (S)
Ertapenem 2 (S)
Gentamicin 2 (S) 4 (S)
Imipenem 2 (S) 4 (S)
Levofloxacin 2 (S) 2 (S)
Meropenem 4 (S) 4 (S)
Moxifloxacin 2 (S) 2 (S)
Tetracycline 8 (I)
Ticarcillin/K clavulanate 16 (S) 16 (S)
Tobramycin 4 (S) 4 (S)
Trimethoprim-sulfamethoxazole 2/38 (S) 2/38 (S)
a S, susceptible; I, intermediate; R, resistant. MICs were determined with the use of the
Siemens MicroScan system using the Gram-negative NC44 tray for the isolate from
blood and NBPC34 tray for the isolate from breast tissue. Formal testing for extended-
spectrum -lactamase production was not performed.




sexa Comorbidity(ies) and/or risk factor(s)b
Site of
infection Initial antibiotic(s) Outcome
1 Rimailho et al. (1987) (16) 74/M NSAID Right leg Not reported Died
2 Zipper et al. (1996) (21) 55/F Diabetes mellitus Right leg Ceftizoxime, clindamycin Survived
3 Huang et al. (1999) (8) 73/M Nephrotic syndrome, corticosteroid Right leg Ciprofloxacin Diedc
4 Huang et al. (1999) (8) 40/M ESRD (hemodialysis), lupus, skin biopsy,
corticosteroid
Left leg Ceftazidime Survived
5 Liangpunsakul and Pursell
(2001) (10)
66/F None Left leg Penicillin G, clindamycin Died
6 Newton et al. (2002) (15) 2/F None Neck Vancomycin, cefotaxime, amikacin, clindamycin Died
7 Bachmeyer et al. (2004) (2) 49/M Lung cancer s/p chemotherapy, ischemic heart
disease, diabetes mellitus
Left leg Piperacillin-tazobactam, amikacin Diedc
8 Curtis et al. (2005) (5) 51/M ESRD (hemodialysis), diabetes mellitus, heart
failure
Left leg Vancomycin, ciprofloxacin, clindamycin Died
9 Statham et al. (2009) (19) 6/M Recurrent otitis media, recurrent pharyngitis Neck Vancomycin, cefepime, clindamycin Survived
10 Present case (2011) 43/F ESRD (hemodialysis), lupus, SVC syndrome,
ligation of arteriovenous fistula, corticosteroid
Chest wall Vancomycin, piperacillin-tazobactam,
ciprofloxacin
Died
a M, male; F, female.
b NSAID, nonsteroidal anti-inflammatory drugs; ESRD, end-stage renal disease; s/p chemotherapy, status postchemotherapy; SVC, superior vena cava.
c Death was from aspiration pneumonia and gastrointestinal bleeding (case 3) or metastatic small cell lung cancer (case 7), not necrotizing fasciitis per se.
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susceptibility profile of the isolated S. marcescens was reported
only by Curtis et al. (5), who found their isolate to be resistant to
ampicillin, cefazolin, and cefuroxime but susceptible to ceftriax-
one, cefepime, piperacillin-tazobactam, imipenem, ciprofloxacin,
and gentamicin. All patients underwent early surgical debride-
ment; nonetheless, 7 out of 10 patients (70%) had a fatal outcome.
Septic shockwithmultiorgan failure was themost frequent patho-
physiological syndrome leading to death.
In our patient, necrotizing fasciitis of the chest wall might have
startedwith direct seeding of the pectoral fascia through a break in
the overlying skin. Alternatively, the chest wall fascia might have
become secondarily involved due to hematogenous dissemina-
tion. Our patient had several predisposing conditions for invasive
soft tissue and bloodstream infections. Chronic hemodialysis and
corticosteroid use have previously been shown to be risk factors
for Gram-negative rod bacteremia (18, 20). Whether prior sple-
nectomy in our patient contributed to infectionwith S.marcescens
is not entirely clear. S.marcescens is not an encapsulated organism,
and splenectomized patients have not been shown to be at in-
creased risk for infections with Serratia spp.
In conclusion, we report a case of fulminant necrotizing fascii-
tis presenting as bilateral breast necrosis. To our knowledge, this is
the first reported case of necrotizing pectoral fasciitis due to infec-
tionwith S.marcescens. Despite the unusual presentation, this case
illustrates the significant morbidity and mortality that can be as-
sociated with S. marcescens infections.Moreover, it highlights that
in patients with lupus and renal failure presenting with necrotiz-
ing fasciitis, the initial antibiotic coverage should be broad enough
to cover for multidrug-resistant Gram-negative bacilli such as S.
marcescens.
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